Skip to main content

Table 2 Summary of the adverse events that occurred in the two treatment groups (safety population)

From: Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

Adverse event Pertuzumab group [cases (%)] n = 83 Control group [cases (%)]n = 80
All-grade AEs 83 (100.0) 78 (97.5)
 Grade 3–5 AEs 67 (80.7) 52 (65.0)
 Serious AEs 17 (20.5) 12 (15.0)
 AEs leading to treatment discontinuation 7 (8.4) 5 (6.3)
 AEs with fatal outcome 3 (3.6) 6 (7.5)
AEs leading to study withdrawal 1 (1.2) 2 (2.5)
  1. AE adverse event